ADPT logo

ADPT Adaptive Biotechnologies Corporation

NASDAQ Global Select · Biotechnology · Healthcare

$27.93
-0.12 (-0.43%)

Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers sever…

Market Cap: $4.52Bwww.adaptivebiotech.com

Price

No data yet.

Social Signal Score

54
5d
54
2 mentions
—
30d
56
12 mentions
—
60d
53
17 mentions
—
90d
53
21 mentions
—
news: 12 · rss: 9

Analyst Ratings

17 analysts
Buyconsensus
Strong Buy 0Buy 11Hold 4Sell 2Strong Sell 0
Avg price target$31.58+13.1%
Low $27Median $33High $35
Current Consensus

Revenue

$83.90M+763.63%
$9.71M$37.80M$65.89M$93.97M
Mar 2018Sep 2026

Analyst Estimates

FY2025
$-0.49
$-0.50–$-0.47
5 analysts
FY2026
$-0.39
$-0.40–$-0.37
4 analysts
FY2027
$-0.07
$-0.11–$0.04
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Chad Robins
Sector
Healthcare
Industry
Biotechnology
Employees
624
Beta
2.15
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
3.26
www.adaptivebiotech.com